





COVID-19 stand van zaken


Prof. dr. 5.1.2e, 22/01/2021

Distribution of COVID-19 cases (according to the applied case definition in the country) by country and region, as of 21 February 2020




Bron: ECDC

Distribution of COVID-19 cases (according to the applied case definition in the country) in EU/EEA and the UK, as of 6 March 2020




RKI (<http://rki.hi-berlin.de/corona/docs/analysis/current/>)



Covid-19 notifications, hospital admission and deaths July – Sept 18


Source: RIVM

Age distribution of new cases, hospitalizations and deaths July 6-Sept 20



Source: RIVM

Indicator for transmission: basic reproduction number (R0), end of August





Source: RIVM

5.1.2e

ecdc.europa.eu


•Distribution of laboratory confirmed cases of COVID-19
•in the EU/EEA and the UK, as of 20 September

14-day COVID-19 case notification rate per 100 000, weeks 36-37




Max 3 guests
Horeca closed, further restrictions
Lockdown, school closure, max 2 pers etc


Ieldingen positief geteste personen per dag vanaf 31 aug 2020





Meest geregistreerde settings bij clusters binnen leeftijdsgroepen




Bron: RIVM/Cib










Clusters: aantallen en grootte – 19-10-2020



Blauw: relatief aandeel verschillende clusters
Oranje: exclusief thuisituatie

Bron: RIVM/Cib

•Acknowledgements: Zaaijer, Slot, Hagemma et al. 2020

•Sanquin


COVID-19 sero-epidemiologie



Sanquin research
Wantai-total-Ab test op antistoffen tegen SARS-CoV-2
vanaf maart stabiele, toenemende seroprevalentie
Zaaijer, Slot, Hogema et al., 2020



Serologische test
Test naar een eerder
doorgemaakte infectie
(ofwel van het
lichaam)




De Kamer Briefing - 28 oktober 2020



- VE against COVID-19 for Pfizer BioNTech
 - 52% after dose 1 (manufacturer)
 - 93% after dose 1 (reanalysis)
 - 95% after dose 2
- VE against COVID-19 for Moderna
 - 80% after dose 1 (manufacturer)
 - 94% after dose 2
- Both mRNA vaccines

Astra Zeneca vaccine submitted to EMA
(vector vaccine)






•CFR for COVID-19 in the Netherlands


<https://ourworldindata.org/mortality-risk-covid#the-case-fatality-rate>

COVID-19



<https://ourworldindata.org/grapher/covid-19-total-confirmed-cases-vs-total-confirmed-deaths>


COVID-19




Acknowledgments: 5.12e

Wrap up! Containment measures

SLIDE I USED TO SHOW BEFORE THE COVID PANDEMIC



Wrap up!



- Brauner et al. medRxiv preprint
- The effectiveness of eight nonpharmaceutical interventions against COVID-19 in 41 countries

